S3-guideline of the German Society of Digestive and Metabolic Diseases and the competence network 'Chronic inflammatory bowel diseases' for the diagnosis and treatment of ulcerative collitis;S3-leitlinie der Deutschen gesellschaft für verdauungs- und stoffwechselerkrankungen und des kompetenznetzes chronisch entzündliche darmerkrankungen zur diagnostik und therapie der colitis ulcerosa: Ein update

Medizinische Klinik

Volumn 100, Issue 1, 2005, Pages 43-50

  Hoffmann, Jörg C ^a   Zeitz, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOSALICYLIC ACID; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; ISPAGULA; LOPERAMIDE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PEGINTERFERON; PREDNISOLONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; VITAMIN D;

DRUG EFFICACY; ENTERITIS; EVIDENCE BASED MEDICINE; HUMAN; LEUKOPENIA; PANCREATITIS; PRACTICE GUIDELINE; PREVALENCE; PROCTITIS; PSYCHOSIS; REMISSION; REVIEW; SIDE EFFECT; TERATOGENICITY; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSCOPY, GASTROINTESTINAL; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MESALAMINE; NATIONAL HEALTH PROGRAMS; PARENTERAL NUTRITION, TOTAL;

PLANTAGO OVATA;

EID: 13144262851     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-005-1119-9     Document Type: Review

References (79)

1. Rosch M, Leidl R, Tirpitz C, et al. [Cost measurement based on a cost diary in patients with inflammatory bowel disease.] Z Gastroenterol 2002;40: 217-28.
2. Stange EF, Riemann J, Herbay A von, et al. Diagnostik und Therapie der Colitis ulcerosa: Ergebnisse einer Evidenz-basierten Konsensuskonterenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen. Z Gastroenterol 2001;39:19-72.
3. Hoffmann JC, Zeitz M, Bischoff SC, et al. Diagnostik und Therapie der Colitis ulcerosa: Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen zusammen mit dem Kompetenznetz chronisch entzündliche Darmerkrankungen. Z Gastroenterol 2004;42:979-1042.
4. Das Leitlinien Manual. Entwicklung und Implementierung von Leitlinien in der Medizin. Z Arzd Fortbild Qualitatssich 2001;95:Suppl 1:1-84.
5. Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983;18:735-42.
6. Gurudu S, Fiocchi C, Katz JA. Inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2002;16: 77-90.
7. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98:1309-14.
8. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861-7.
9. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363-72.
10. Kaufman HS, Kahn AC, Iacobuzio Donahue C, et al. Cytomegaloviral enterocolitis: clinical associations and outcome. Dis Colon Rectum 1999;42:24-30.
11. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122: 1242-7.
12. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ul cerative colitis. Am J Gastroenterol 1997;92:1867-71.
13. Danish 5-ASA Group. Topical 5 aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Dig Dis Sci 1987;32:598-602.
14. Campieri M, Gionchetti P, Belluzzi A, et al. Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig Dis Sci 1987; 32:67S-70S.
15. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta analysis. Aliment Pharmacol Ther 1995;9:293-300.
16. Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991;32: 929-31.
17. Hanauer SB. Dose ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis 1998;4:79-83.
18. Danielsson A, Hellers G, Lyrenas E, et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987;22:987-92.
19. Danielsson A, Lofberg R, Persson T, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992;27:9-12.
20. Lofberg R, Ostergaard Thomsen O, Langholz E, et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994;8:623-9.
21. Baron JH, Connell AM, Kanaghinis TG, et al. Outpatient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962;5302:441-3.
22. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
23. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993;88:1188-97.
24. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 1991;115:350-5.
25. Meyers S, Sachar DB, Present DH, et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987;93: 1255-62.
26. Feurle GE, Theuer D, Velasco S, et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut 1989;30:1354-61.
27. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955: 1041-8.
28. Oshitani N, Kitano A, Matsumoto T, et al. Corticosteroids for the management of ulcerative colitis. J Gastroenterol 1995;30:Suppl 8:118-20.
29. D'Haens G, Lemmens L, Geboes K, et al. Intravenous single therapy for severe attacks of ulceradve colitis. Gastroenterology 2001;120:1323-9.
30. Gasche C, Lomer MC, Cavill I, et al. Iron, anaemia, and inflammatory bowel diseases. Gut 2004;53:1190-7.
31. Luebke H, Meier R, Lochs H, et al. DGEM-Leitlinie Enterale Ernährung: Gastroenterologie. Akt Ernaehr Med 2003;Suppl 1:69-86.
32. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38: 905-10.
33. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831-5.
34. Meyers S, Lerer PK, Feuer EJ, et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double blind clinical trial. J Clin Gastroenterol 1987;9:50-4.
35. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
36. Meyers S, Sachar DB, Goldberg JD, et al. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 1983;85: 351-7.
37. Van Assche G, D'Haens G, Noman M, et al. Randomized, double blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31.
38. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003;17:1273-81.
39. Fellermann K, Ludwig D, Stahl M, et al. Steroid unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998;93:1860-6.
40. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002;8:317-24.
41. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999;94:1587-92.
42. Fernandez Banares F, Bertran X, Esteve Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:2498-9.
43. Sood A, Kaushal V, Midha V, et al. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002;37:270-4.
44. Ardizzone S, Petrillo M, Imbesi V, et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 1999; 13:373-9.
45. Kornbluth AA, Salomon P, Sacks HS, et al. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J Clin Gastroenterol 1993;16: 215-8.
46. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993;118:540-9.
47. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
48. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic E. coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
49. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
50. Kirk AP, Lennard Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J [Clin Res] 1982;284:1291-2.
51. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992;305:20-2.
52. Boulton Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000;14:1561-5.
53. Bowen DG, Selby WS. Use of 6 mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000;45: 1810-3.
54. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
55. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population based study. N Engl J Med 1990;323:1228-33.
56. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54.
57. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8:1179-83.
58. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145-53.
59. Melville DM, Jass JR, Shepherd NA, et al. Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology 1988;95:668-75.
60. Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992;103:1611-20.
61. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71-4.
62. Befrits R, Ljung T, Jaramillo E, et al. Low grade dysplasia in extensive, long standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 2002;45:615-20.
63. Lim CH, Dixoni MF, Vail A, et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003;52:1127-32.
64. Ullman TA. Patients with low grade dysplasia should be advised to undergo colectomy. Inflamm Bowel Dis 2003;9:267-9, discussion 273-5.
65. Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999;117:1288-94, discussion 1488-91.
66. Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999;117:1295-300.
67. Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease. J Clin Gastroenterol 2004;38:S44-50.
68. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
69. Sandborn WJ, McLeod R, Jewell DP. Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Inflamm Bowel Dis 1999;5:33-9.
70. Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitis - a double-blind, double-dummy controlled trial. Aliment Pharmacol Ther 2002;16: 27-34.
71. Harnois DM, Angulo P, Jorgensen RA, et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
72. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121: 900-7.
73. Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001;53:308-12.
74. Stiehl A, Rudolph G, Kloters Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002;36:151-6.
75. Bitton A, Sewitch MJ, Peppercorn MA, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol 2003;98:2203-8.
76. Levenstein S, Prantera C, Varvo V, et al. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study Am J Gastroenterol 1994;89:1219-25.
77. Chen ZS, Nie ZW, Sun QL. [Clinical study in treating intractable ulcerative colitis with traditional Chinese medicine.] Zhongguo Zhong Xi Yi Jie He Za Zhi 1994;14:400-2.
78. Chen Z. Treatment of ulcerative colitis with acupuncture. J Tradit Chin Med 1995;15:231-3.
79. Wu HG, Zhou LB, Shi DR, et al. Morphological study on colonic pathology in ulcerative colitis treated by moxibustion. World J Gastroenterol 2000;6: 861-5.